AAI Hosted Event
AAI Competition Roundtable: Stemming the Tide of Competitive and Consumer Harm in Pharmaceutical Markets
On Wednesday, October 2, 2019, the American Antitrust Institute will host a competition roundtable “Stemming the Tide of Anti-Competitive Harm in Pharmaceuticals” at the National Press Club in Washington, D.C.
The roundtable will take up competition enforcement and policy issues involving the pharmaceutical industry, their major impact on the healthcare system and on consumers, and policy prescriptions for improving competition. Experts in antitrust and regulation from government, industry, advocacy, and academia will frame major competitive issues through the lens of different stakeholder and enforcement perspectives.
The half-day program will feature a keynote address, legislative briefing, and two panels followed by a roundtable discussion. The legislative briefing will weave together the various pieces of proposed legislation introduced in the 116th Congress involving drug pricing and practices that block market entry and slow innovation. The first panel will examine the burgeoning set of practices and strategies deployed by both branded and generic drug companies that stifle competition and raise prices to consumers. The second panel will feature multidisciplinary perspectives to framing responses to stemming the tide of anticompetitive harm in pharmaceuticals, arguably a crisis of epic proportions in our economy. The day will close with a roundtable session that gives participants the opportunity to react to and candidly discuss themes, issues, and policy recommendations for competition enforcement.
Panel 1: Unpacking the Law and Economics of New Approaches to Limiting Competition in Pharmaceutical Markets
The opening panel will examine the burgeoning set of practices and strategies deployed by both branded and generic drug companies that are designed to limit competition and raise prices to consumers. With stronger law regarding pay for delay, drug companies have moved on to newer ways to delay market entry and keep drug prices high. These include practices such as product hopping, sham petitioning, and price fixing. The panel will also discuss competition issues in the pharmacy benefit manager (PBM) segment of the supply chain and the potential spillover effects of certain PBM practices into the upstream drug manufacturing sector. Panelists will provide perspective and insight into how these issues have been addressed by public and private enforcement, judicial successes and losses in combating abusive behavior, and their implications for competition, consumers, and innovation.
Panel 2: Policy Responses to Promoting Competition in Pharmaceutical Markets
This panel will feature multidisciplinary perspectives for framing responses to stemming the tide of competitive and consumer harm in pharmaceutical markets. Drugs represent a significant part of total healthcare spending in the U.S. and an aging population will put additional pressure on the pharmaceutical innovation and distribution system. Given the importance of the pharmaceutical sector, antitrust enforcement will need to be buttressed by a coherent competition, patent, and public health policy framework. Panelists from healthcare, enforcement, and state and federal policy forums will weave the major takeaways from the first panel together with their unique perspectives. They will discuss the policy implications of the current crisis in drugs and provide insight into the elements of an integrated policy approach to promoting continued innovation, fair prices, and access to drugs by those who need them.
Event Location:National Press Club
529 14th Street NW, 13th Floor
Washington, DC 20045
Members of the media are present at most AAI roundtables. Speakers and participants should be aware that the media are on background during AAI events. If a member of the media wishes to quote or cite from the live proceedings of AAI events, they are asked to contact specific sources for permission.
This roundtable will be submitted for CLE credit hours. A Uniform Certificate of Attendance was emailed to all attendees following the conference.